Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / RHHBY - Halozyme Therapeutics: A Reasonable Value In An Overvalued Market

RHHBY - Halozyme Therapeutics: A Reasonable Value In An Overvalued Market

Roche Holding Ltd ADR

2024-01-26 12:47:12 ET

Summary

  • Today, we take another look at Halozyme Therapeutics, Inc., which enhances drug delivery through its ENHANZE platform, earning royalties and milestone payouts from major drugmakers.
  • Management has plans in place to more than double royalty revenues by FY2027 and the stock is a reasonable value in an overvalued market.
  • An updated analysis of Halozyme Therapeutics follows in the paragraphs below.

Debt is the slavery of the free ." - Publilius Syrus.

It has been just over a year since I posted my last take on Halozyme Therapeutics, Inc. ( HALO ) . This name comes up occasionally in comments from Seeking Alpha followers, and it feels like it is time to circle back on this mid-cap biotech name. An updated analysis follows below....

For further details see:

Halozyme Therapeutics: A Reasonable Value In An Overvalued Market
Stock Information
Company Name: Roche Holding Ltd ADR
Stock Symbol: RHHBY
Market: OTC
Website: roche.com
Menu
RHHBY RHHBY Quote RHHBY Short RHHBY News RHHBY Articles RHHBY Message Board
Get RHHBY Alerts

News, Short Squeeze, Breakout and More Instantly...